2,3-二氢-1-苯并呋喃-5-甲醇 | 103262-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2,3-二氢-1-苯并呋喃-5-甲醇
• 中文别名: 2,3-二氢-1-苯并呋喃-5-基甲醇；2,3-二氢苯并[B]呋喃-5-甲醇；2,3-二氢-1-苯并呋喃-6-基甲醇
• 英文名称: 2,3-dihydrobenzofuran-5-methanol
• 英文别名: (2,3-dihydrobenzofuran-5-yl)methanol；(2,3-dihydrobenzo[b]furan-5-yl)methanol；2,3-dihydro-5-benzofuranmethanol；5-hydroxymethyl-2,3-dihydro-benzofuran；2,3-dihydro-1-benzofuran-5-ylmethanol
• CAS: 103262-35-7
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: XQDNBMXUZGAWSZ-UHFFFAOYSA-N

物化性质

• 沸点：
  152-155 °C(Press: 8 Torr)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	2 3-Dihydro-1-benzofuran-5-ylmethanol 97% Material Safety Data Sheet
Synonym:
CAS:	103262-35-7

Section 1 - Chemical Product MSDS Name:2 3-Dihydro-1-benzofuran-5-ylmethanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
103262-35-7	2,3-Dihydro-1-benzofuran-5-ylmethanol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 103262-35-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 138 - 140 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H10O2
Molecular Weight: 150

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 103262-35-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydro-1-benzofuran-5-ylmethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 103262-35-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 103262-35-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 103262-35-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1-苯并呋喃-5-甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 5-氯甲基-2,3-二氢苯并呋喃
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  The invention relates to compounds of formula (la) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: Formula (Ia) wherein RA, RB, RCand RD, X, m and n are as defined herein.

  公开号：

  WO2023052783A1
• 作为产物：
  描述：

  2,3-二氢苯并呋喃-5-甲醛 在 sodium borohydrid 作用下， 以 甲醇 为溶剂， 生成 2,3-二氢-1-苯并呋喃-5-甲醇
  参考文献：
  名称：

  Tricyclic compounds, their production and use

  摘要：

  该化合物的结构式为：##STR1## 其中R.sup.1是可选择取代的碳氢化合物、氨基或杂环基团；R.sup.2是H或可选择取代的碳氢基团；R.sup.3是H或可选择取代的碳氢或杂环基团；X是CHR.sup.4、NR.sup.4、O或S，其中R.sup.4是H或可选择取代的碳氢基团；Y是C、CH或N；环A是可选择取代的5-至7-成员环；环B是可选择取代的苯环；m为1至4，或其盐，提供了其制备方法、生产中间体和包含它的药物组合物。

  公开号：

  US06034239A1

文献信息

• Tricyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06034239A1

  公开（公告）日：2000-03-07

  A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.

  该化合物的结构式为：##STR1## 其中R.sup.1是可选择取代的碳氢化合物、氨基或杂环基团；R.sup.2是H或可选择取代的碳氢基团；R.sup.3是H或可选择取代的碳氢或杂环基团；X是CHR.sup.4、NR.sup.4、O或S，其中R.sup.4是H或可选择取代的碳氢基团；Y是C、CH或N；环A是可选择取代的5-至7-成员环；环B是可选择取代的苯环；m为1至4，或其盐，提供了其制备方法、生产中间体和包含它的药物组合物。
• Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1199304A1

  公开（公告）日：2002-04-24

  A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

  具有以下一般式的化合物： 其中R1是可选择取代的碳氢化合物、氨基或杂环基团；R2是H或可选择取代的碳氢基团；R3是H或可选择取代的碳氢基团或杂环基团；X是CHR4、NR4、O或S，其中R4是H或可选择取代的碳氢基团；R5是H、卤素原子、C1-6烷基基团、C1-6烷氧基团、羟基、硝基、氰基或氨基，其中C1-6烷基基团、C1-6烷氧基团和氨基可能被1至5个取代基取代，Y是C或N；环B是可选择取代的苯环；m = 1至4，n = 0至2；L代表离去基团，如卤素原子、烷基磺酰基团、烷基磺酰氧基团和芳基磺酰氧基团；或其盐。
• 苯并五元氧杂环-苯并咪唑盐类化合物及其合成方法与应用
  申请人：云南大学

  公开号：CN110357866A

  公开（公告）日：2019-10-22

  本发明公开了苯并五元氧杂环‑苯并咪唑盐类化合物及其合成方法与应用，属于药物化学技术领域。本发明苯并五元氧杂环‑苯并咪唑盐类化合物的结构式为其中，当X＝O，Y＝CH2时，R1、R2＝H，R3＝2‑萘甲酰甲基，R1＝CH3，R2＝H，R3＝2‑萘甲酰甲基，R1＝H，R2＝CH3，R3＝2‑萘甲酰甲基，4‑溴苄基，2‑萘甲基，4‑甲基苄基，2‑溴苄基；当X＝CH2，Y＝C═O时，R1、R2＝H，R3＝2‑萘甲酰甲基，R1＝CH3，R2＝H，R3＝2‑萘甲酰甲基，R1＝H，R2＝CH3，R3＝2‑萘甲酰甲基，2‑溴苄基；当X＝CH2，Y＝CH2时，R1＝H，R2＝CH3，R3＝2‑萘甲酰甲基，2‑溴苄基。本发明化合物与至少一种药物上可接受的赋型剂、稀释剂或载体制得的药物可用于肿瘤癌症。
• Highly sulphated cellulose: a versatile, reusable and selective desilylating agent for deprotection of alcoholic TBDMS ethers
  作者：Soma Shekar Dachavaram、Narsimha R. Penthala、Julie L. Calahan、Eric J. Munson、Peter A. Crooks

  DOI：10.1039/c8ob01438h

  日期：——

  A mild, efficient and rapid protocol was developed for the deprotection of alcoholic TBDMS ethers using a recyclable, eco-friendly highly sulphated cellulose sulphate acid catalyst in methanol. This acid catalyst selectively cleaves alcoholic TBDMS ethers in bis-TBDMS ethers containing both alcoholic and phenolic TBDMS ether moieties.

  开发了一种温和，有效和快速的方案，使用可回收的，环境友好的高度硫酸化的硫酸纤维素硫酸酯催化剂在甲醇中脱醇TBDMS醚。该酸催化剂在含有醇和酚TBDMS醚部分的双-TBDMS醚中选择性裂解醇TBDMS醚。
• Prokineticin 1 receptor antagonists
  申请人：Coats Steven J.

  公开号：US20080269225A1

  公开（公告）日：2008-10-30

  The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：以及制备这些化合物、组合物、中间体和衍生物的方法，以及用于治疗促动素1或促动素1受体介导的疾病的方法。